| Name | Title | Contact Details |
|---|
Regulatory compliance software solutions, products and services assist pharmaceutical, medical device and biotechnology companies in complying with marketing and sales regulations.
Promentis Pharmaceuticals, Inc., is a privately held biopharmaceutical company focused on the discovery and development of first-in-class therapies to treat central nervous system (CNS) disorders. Promentis` drug development program is focused on activating a unique target known to restore glutamatergic neurotransmission and imbalances in oxidative stress, key contributors to impaired cortical function linked to multiple CNS disorders. The Company`s lead compound, SXC-2023, is being developed to treat various psychiatric disorders, with an initial focus on an indication that, despite representing a common disorder affecting millions of patients, has no FDA-approved treatment and a high level of patient need.
Save time, money and resources with the smarter, simpler, and safer way to handle regulated medical waste
High Definition means improved diagnostic results through a superior vision. At Strauss, visualization is at the core of who we are, and what we do best.
Asembia constantly connects and strengthens the pharmaceutical industry to improve the experiences of patients everywhere.